A detailed history of Ahrens Investment Partners LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Ahrens Investment Partners LLC holds 400 shares of CRSP stock, worth $18,516. This represents 0.01% of its overall portfolio holdings.

Number of Shares
400
Holding current value
$18,516
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 21, 2023

BUY
$41.0 - $56.12 $16,400 - $22,448
400 New
400 $18,000
Q4 2021

Jan 21, 2022

BUY
$70.09 - $111.29 $4,555 - $7,233
65 New
65 $5,000
Q1 2021

May 05, 2021

SELL
$110.72 - $210.04 $186,563 - $353,917
-1,685 Closed
0 $0
Q4 2020

Feb 02, 2021

BUY
$79.67 - $173.23 $134,243 - $291,892
1,685 New
1,685 $258,000
Q3 2018

Nov 09, 2018

SELL
$44.35 - $65.71 $151,455 - $224,399
-3,415 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$42.62 - $73.59 $145,547 - $251,309
3,415 New
3,415 $201,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.61B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Ahrens Investment Partners LLC Portfolio

Follow Ahrens Investment Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ahrens Investment Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ahrens Investment Partners LLC with notifications on news.